Pharma major Lupin announced the launch of its Oseltamivir Phosphate Capsules, used for treatment of influenza in the US markets.
The company said in a BSE filing that it has launched its tablets after receiving the approval from the United States Food and Drug Administration (USFDA).
Lupin’s Oseltamivir Phosphate Capsules, USP, 30 mg (base), 45 mg (base), and 75 mg (base) are the generic equivalent of Hoffman-La Roche, Inc.’s Tamiflu®Capsules, 30 mg, 45 mg, and 75 mg.
Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base) are indicated for the treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours, and prophylaxis of influenza A and B in patients 1 year and older.
The capsules had annual sales of about US $518 million in the US as per IQVIA MAT December 2017 data
